Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The Center for HIV/AIDS Vaccine Development (CHAVD), a consortium of researchers at Scripps Research and Duke University, was informed last month that, after seven years of funding from NIH, their ...

In an interview with The News & Observer, Dr. Barton Haynes discusses the future of HIV vaccine development after HHS canceled the Center for HIV/AIDS Vaccine Development.

The research at CHAVD consists of multiyear investments in advanced HIV vaccine technologies, but it has also already yielded improvements in treatment of other conditions, including COVID-19, snake ...